Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
10.1165/rcmb.2023-0038OC 37 YanqingL.ZhangC.ChengH.LvL.ZhuX.MaM.et al (2024)
The core of this litigation targets major pharmaceutical companies, Novo Nordisk and Eli Lilly and Co., accusing them of failing to sufficiently warn users about the severe digestive side effects of GLP-1 class drugs, typically prescribed for diabetes management and weight loss
Its dual incretin mimetic profile has been the subject of extensive in vitro receptor binding and signal transduction research
Balthasar N, Dalgaard LT, Lee CE, Yu J, Funahashi H, Williams T, et al
US$ 27.18
US$ 24.03
US$ 25.46
US$ 26.57
US$ 28.69
US$ 25.41
